Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.

Q2 2025 Earnings Call Transcript July 24, 2025 RPC, Inc. misses on earnings expectations. Reported EPS is $0.04652 EPS, ...

Singh highlighted the current status and key milestones achieved in the Gaganyaan program. “ Human Rated Launch Vehicle ...

On this episode of “Uncanny Valley,” we dive into the heated race between two companies to build a commercial brain-computer ...

In a region defined by intense military and technological challenges, preserving Türkiye's deterrent power is ...

Ola Electric's focus on profitability has led to a market share decline, with Ather Energy closing the gap. The electric ...

The FDA had asked Sarepta to voluntarily halt all shipments of Elevidys following the deaths of three nonambulatory Duchenne ...

W E-Bike Regulation, Lobbying Failures, and a Vision for the Industry. How we’re currently undermining ourselves – and what ...

HG, a small family-owned Danish OEM, is making a big impact with its new battery electric E2000 dumper – driven by innovative ...

Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...